Circulating Innate Lymphoid Cell Type 2 (ILC2) Levels and Asthma: a Case-control Study
- Conditions
- Asthma
- Interventions
- Biological: ILC2 levels in blood
- Registration Number
- NCT03128762
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
The primary objective of this study is to demonstrate differences in ILC2 blood levels between asthma patients and control patients.
- Detailed Description
The secondary objectives of this study are:
To show that ILC2 levels differ between asthma patients with a "TH2" (helper T cell type 2) profile and asthma patients with a "non-TH2" profile. A TH2 profile is defined as (for a given patient):
* circulating eosinophils \> 500 mm\^3 at least once during the year AND
* positive allergy skin or specific IgE (Immunoglobulin E) test AND
* induced sputum eosinophil level \>3% of leukocytes AND
* exhaled nitric oxide \> 25 ppb.
To study the variation in ILC2 levels over time among asthma patients who obtained a good level of control compared to other patients. A good level of control is defined as:
* no exacerbations during 6 months of followup (an exacerbation is defined as the un-planned need for care that modifies the patient's prescription for \>48h)
* FEV1 (forced expiratory volume in 1 second) value current / FEV1 best value \> 0.8
* symptom levels correspond to an ACQ (Asthma Control Questionnaire) questionnaire score of \< 0.75 over the last 7 days
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cases ILC2 levels in blood Patients in this group are asthmatic (see inclusion/exclusion) criteria. Intervention: ILC2 levels in blood Controls ILC2 levels in blood Controls are non-asthmatic subjects that are age and gender matched to asthma cases. Intervention: ILC2 levels in blood
- Primary Outcome Measures
Name Time Method % ILC2 cells among total blood lymphocytes Day 0 Determined by flow cytometry
- Secondary Outcome Measures
Name Time Method % ILC2 cells among total blood lymphocytes 6 months Determined by flow cytometry; Asthma patients only.